Hims stock took a nasty hit last week.
This, after the FDA announced there was no longer a shortage of semaglutide injection products.
This matters, because the company Hims & Hers (NYSE: HIMS), prescribes “compounded semaglutide.” The company is considered a “compounder,” which means it produces custom-made alternatives to brand names during shortages. In this case, it’s semaglutide.
And now that the shortage is over, the company can no longer sell its compounded semaglutide. So with that, the stock fell more than 25% on Friday. But I’m not sure I’d bet against Hims stock over the long haul. Our analysts have traveled the world over, dedicated to finding the best and most profitable investments in the global energy markets. All you have to do to join our Energy and Capital investment community is sign up for the daily newsletter below.The Best Free Investment You’ll Ever Make
Hims Stock for the Win
Last May, I gave you my thoughts on Hims stock, where I noted that I expected the stock to be trading at around $16.50 a share by December. At the time, you could’ve picked some up for less than $13.00.
Well, it did end up hitting $16.50 a share — and then some!
Last week, the stock hit a new high of $72.98. That’s a 461% gain based on when I suggested it was an undervalued stock.
But Hims stock finally pulled back after that FDA announcement.
To be fair, I don’t believe the stock is worth $72.98. And in fact, even after that 25% haircut, I believe the stock is still a bit overpriced. Still, this is not a company I would bet against. After all, even after last week’s sell-off, had you bought it when I suggested it was undervalued, you’d still be up more than 276%.
What really started out as a boner bill company has transformed into a legitimate contender in the world of personalized medications and treatments. We’re talking about everything from cognitive performance and preventative health to metabolic optimization and recovery science.
In fact, just prior to the FDA announcement, the company made a very interesting acquisition. It bought a company called Trybe Labs, which makes at-home medical testing kits for cholesterol, hormone abnormalities, stress markers, liver function, thyroid function and prostate health.
The truth is, one day, it will be completely unnecessary to go to a dedicated lab to get a blood test. "At-home" medical testing kits are the future. And Hims is getting an early piece of this action.
Now, it’s hard to say if Hims stock will be able to ride another wave of semaglutide shortages. But because the company has expanded so rapidly, and continues to cast a wide net, I suspect it is in no danger of going gently into that good night.
Would I buy it at these levels? No. But once the dust settles, there could be another opportunity to make a few bucks from this thing.
Of course, I want to make more than just a few bucks. Which is one of the reasons I'm so bullish on this bitcoin loophole strategy that’s already allowed us to score gains in excess of 6,700%. You can look at the actual numbers right here, too.
Indeed, as a long-term play on personalized medication and treatments, I do like Hims stock. But it’ll never deliver the kind of gains you’re going to see from this bitcoin loophole strategy.
To a new way of life and a new generation of wealth…
Jeff Siegel
Check us out on YouTube!
@JeffSiegel on Twitter
Jeff is an editor of Energy and Capital as well as a contributing analyst for New World Assets.
Want to hear more from Jeff? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.
